Braskie Meredith N, Thompson Paul M
Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, California; Department of Neurology, University of Southern California, Los Angeles, California.
Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, California; Department of Neurology, University of Southern California, Los Angeles, California; Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, California; Department of Radiology, University of Southern California, Los Angeles, California; Department of Pediatrics, University of Southern California, Los Angeles, California; Department of Ophthalmology, University of Southern California, Los Angeles, California; Keck School of Medicine, and Viterbi School of Engineering, University of Southern California, Los Angeles, California.
Biol Psychiatry. 2014 Apr 1;75(7):527-33. doi: 10.1016/j.biopsych.2013.11.020. Epub 2013 Nov 28.
In recent years, numerous laboratories and consortia have used neuroimaging to evaluate the risk for and progression of Alzheimer's disease (AD). The Alzheimer's Disease Neuroimaging Initiative is a longitudinal, multicenter study that is evaluating a range of biomarkers for use in diagnosis of AD, prediction of patient outcomes, and clinical trials. These biomarkers include brain metrics derived from magnetic resonance imaging (MRI) and positron emission tomography scans as well as metrics derived from blood and cerebrospinal fluid. We focus on Alzheimer's Disease Neuroimaging Initiative studies published between 2011 and March 2013 for which structural MRI was a major outcome measure. Our main goal was to review key articles offering insights into progression of AD and the relationships of structural MRI measures to cognition and to other biomarkers in AD. In Supplement 1, we also discuss genetic and environmental risk factors for AD and exciting new analysis tools for the efficient evaluation of large-scale structural MRI data sets such as the Alzheimer's Disease Neuroimaging Initiative data.
近年来，众多实验室和研究联盟利用神经影像学来评估阿尔茨海默病（AD）的风险及病情进展。阿尔茨海默病神经影像学计划是一项纵向多中心研究，正在评估一系列用于AD诊断、患者预后预测及临床试验的生物标志物。这些生物标志物包括源自磁共振成像（MRI）和正电子发射断层扫描的脑指标，以及源自血液和脑脊液的指标。我们重点关注2011年至2013年3月期间发表的阿尔茨海默病神经影像学计划研究，这些研究中结构MRI是主要的结果测量指标。我们的主要目标是回顾关键文章，这些文章深入探讨了AD的病情进展以及结构MRI测量指标与AD认知及其他生物标志物之间的关系。在补充材料1中，我们还讨论了AD的遗传和环境风险因素，以及用于高效评估大规模结构MRI数据集（如阿尔茨海默病神经影像学计划数据）的令人兴奋的新分析工具。
